[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368978-105":59,"doc-detail-368978-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","functional-characterization-of-vs-186b-a-novel-hdac-inhibitor-with-anticancer-activity","Functional Characterization of VS-186B, a Novel HDAC Inhibitor with Anticancer Activity","","Histone acetylation and deacetylation regulate gene expression and are often disrupted in cancer, enabling tumor growth and therapy resistance. Histone deacetylases (HDACs) are overexpressed in multiple tumor types, suppressing genes such as p53 and p21. This study evaluated a series of novel HDAC inhibitors for selective anticancer activity and reduced toxicity to non-cancerous cells using DNS assays, flow cytometry, and HDAC inhibition assays, identifying VS-186B as an apoptosis-inducing, Class I/II HDAC inhibitor with favorable selectivity and leukemia/lymphoma relevance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/functional-characterization-of-vs-186b-a-novel-hdac-inhibitor-with-anticancer-activity/368978/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/functional-characterization-of-vs-186b-a-novel-hdac-inhibitor-with-anticancer-activity/368978.png","ImageObject",300,407,{"name":92,"@type":93},"RuangKosong","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main objective of the study on VS-186B?","Question",{"text":112,"@type":113},"The study aimed to identify novel HDAC inhibitors that selectively target cancer cells while minimizing toxicity to non-cancerous cell lines.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was VS-186B evaluated for anticancer activity and selectivity?",{"text":117,"@type":113},"VS-186B and related compounds were tested using the Differential Nuclear Staining (DNS) assay, flow cytometry, and HDAC inhibition assays to assess cytotoxicity, selectivity, and cell-death mechanisms.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism of cell death did VS-186B induce?",{"text":121,"@type":113},"Flow cytometry experiments showed that VS-186B induced apoptosis, supported by Annexin V-FITC and additional apoptosis-related assays.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368978,1790739474,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090883219,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Article  \nFunctional Characterization of VS-186B, a Novel HDAC Inhibitor with Anticancer Activity  \nLaura A. Sanchez-Michael 1,†, Vijayalakshmi Sudarshan 2,3,4,†, Allison Elias 1, Denisse A. Gutierrez 1, Jose A. Lopez-Saenz 1, Jaqueline Pena-Zacarias 1, Gabriela C. Torres 1, Armando Varela-Ramirez 1, Sujeet Kumar 5, Subhas S. Karki 2,3, * and Renato J. Aguilera 1, *  \nAcademic Editor: Alexey Nazarov  \nReceived: 25 September 2025  \nRevised: 10 November 2025  \nAccepted: 16 November 2025  \nPublished: 24 November 2025  \nCitation: Sanchez-Michael, L.A.; Sudarshan, V.; Elias, A.; Gutierrez, D.A.; Lopez-Saenz, J.A.; Pena-Zacarias, J.; Torres, G.C.; Varela-Ramirez, A.; Kumar, S.; Karki, S.S.; et al. Functional Characterization of VS-186B, a Novel HDAC Inhibitor with Anticancer Activity. Int. J. Mol. Sci. 2025, 26, 11354. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms262311354  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Department of Biological Sciences, Border Biomedical Research Center, The University of Texas at El Paso, El Paso, TX 79968, USA; [lasanchez17@miners.utep.edu](lasanchez17@miners.utep.edu) (L.A.S.-M.); [aelias10@miners.utep.edu](aelias10@miners.utep.edu) (A.E.); [dagutierrez18@miners.utep.edu](dagutierrez18@miners.utep.edu) (D.A.G.); [jalopez62@miners.utep.edu](jalopez62@miners.utep.edu) (J.A.L.-S.); [jpenazacar@miners.utep.edu](jpenazacar@miners.utep.edu) (J.P.-Z.); [torresg7@uthscsa.edu](torresg7@uthscsa.edu) (G.C.T.); [avarela2@utep.edu](avarela2@utep.edu) (A.V.-R.)  \n2 Department of Pharmaceutical Chemistry, KLE College of Pharmacy, Bengaluru 560010, Karnataka, India; [vijayalakshmis.py.ph@msruas.ac.in](vijayalakshmis.py.ph@msruas.ac.in)  \n3 KLE Academy of Higher Education and Research, KLE Deemed to be University, Belagavi 590010, Karnataka, India  \n4 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, M.S. Ramaiah University of Applied Sciences, Bengaluru 560054, Karnataka, India  \n5 Department of Pharmaceutical Chemistry, NITTE College of Pharmaceutical Sciences, Nitte-Deemed to be University, Bengaluru 560064, Karnataka, India; [klempharma@gmail.com](klempharma@gmail.com)  \n* Correspondence: [subhashskarki@klepharmblr.org](subhashskarki@klepharmblr.org) (S.S.K.); [raguilera@utep.edu](raguilera@utep.edu) (R.J.A.)† These authors contributed equally to this work.  \nAbstract  \nHistone acetylation and deacetylation are key regulators of gene expression and are frequently dysregulated in cancer, contributing to tumorigenesis and drug resistance. Overexpression of histone deacetylases (HDACs) in many cancer types leads to silencing of tumor suppressor genes and uncontrolled proliferation. Tumors often rely on epigenetic mechanisms to escape therapy and develop resistance. This study aimed to identify novel compounds that selectively target cancer cells while minimizing toxicity to non-cancerous cell lines. A series of novel HDAC inhibitors was evaluated using the Differential Nuclear Staining (DNS) assay, flow cytometry, and HDAC inhibition assays. These assays assessed cytotoxicity, selectivity, and mechanisms of cell death. Among seven compounds tested, VS-186B exhibited the highest cytotoxicity and Selective Cytotoxicity Index (SCI), particularly against the human Jurkat T-cell leukemia cell line. Flow cytometry experiments (Annexin V-FITC, ROS, JC-1, and Caspase-3/7 assays) revealed that VS-186B induced apoptosis. VS-186B was more cytotoxic than Curcumin and Vorinostat across most of the cell lines tested and was more specific to hematological cells. Connectivity Map (CMap) analysis showed strong similarity to genes affected by known HDAC inhibitors. Subsequently, HDAC enzym","cbCaiaITCycHkS5R","https://ap.wps.com/l/cbCaiaITCycHkS5R","pdf",1318461,22,"English","# Abstract\n# Introduction\n## Epigenetic regulation and histone acetylation/deacetylation\n## HDAC overexpression in cancer and rationale for HDAC inhibition\n## Limitations of current HDAC inhibitors\n# Materials and Methods\n# Results\n## Cytotoxicity and selective cytotoxicity index\n## Flow cytometry evidence of apoptosis\n## Comparison with Curcumin and Vorinostat\n## Connectivity Map (CMap) gene-similarity analysis\n## Dose-dependent Class I/II HDAC enzymatic inhibition\n# Discussion\n# Conclusions","[{\"question\":\"What is the main objective of the study on VS-186B?\",\"answer\":\"The study aimed to identify novel HDAC inhibitors that selectively target cancer cells while minimizing toxicity to non-cancerous cell lines.\"},{\"question\":\"How was VS-186B evaluated for anticancer activity and selectivity?\",\"answer\":\"VS-186B and related compounds were tested using the Differential Nuclear Staining (DNS) assay, flow cytometry, and HDAC inhibition assays to assess cytotoxicity, selectivity, and cell-death mechanisms.\"},{\"question\":\"What mechanism of cell death did VS-186B induce?\",\"answer\":\"Flow cytometry experiments showed that VS-186B induced apoptosis, supported by Annexin V-FITC and additional apoptosis-related assays.\"}]","Functional Characterization of VS-186B, a Novel HDAC Inhibitor with Anticancer Activity | PDF",1790180004,55,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9a92642696c15e6efe987e38ea84dbf8.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2c36c35c7b280e1b9d7d55aaf699f4d5.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/50fd28115b4dd03fbba7ee214141a454.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8dd415c7279bbf6f01d1c1dfc2ec8e5c.webp",980,1385]